Versant Venture Management, LLC Buys Gritstone Oncology Inc, Sells Veracyte Inc, Audentes Therapeutics Inc, CymaBay Therapeutics Inc

Jul 12, 2019

San Francisco, CA, based Investment company Versant Venture Management, LLC (current portfolio) buys Gritstone Oncology Inc, sells Veracyte Inc, Audentes Therapeutics Inc, CymaBay Therapeutics Inc during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Versant Venture Management, LLC. As of 2019Q2, Versant Venture Management, LLC owns 8 stocks with a total value of $343 million. These are the details of the buys and sells.

New Purchases: GRTS,
Reduced Positions: VCYT, BOLD, CBAY,

For the details of Versant Venture Management, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/versant+venture+management%2C+llc/current-portfolio/portfolioportfolio

These are the top 5 holdings of Versant Venture Management, LLC

CRISPR Therapeutics AG (CRSP) - 4,248,888 shares, 58.32% of the total portfolio.
Veracyte Inc (VCYT) - 2,410,815 shares, 20.03% of the total portfolio. Shares reduced by 33.33%
Gritstone Oncology Inc (GRTS) - 3,102,929 shares, 10.07% of the total portfolio. New Position
Audentes Therapeutics Inc (BOLD) - 553,916 shares, 6.11% of the total portfolio. Shares reduced by 31.03%
Ocular Therapeutix Inc (OCUL) - 2,215,384 shares, 2.84% of the total portfolio.

New Purchase: Gritstone Oncology Inc (GRTS)

Versant Venture Management, LLC initiated holding in Gritstone Oncology Inc. The purchase prices were between $9.2 and $15.7, with an estimated average price of $11.46. The stock is now traded at around $12.28. The impact to a portfolio due to this purchase was 10.07%. The holding were 3,102,929 shares as of .

Reduced: Veracyte Inc (VCYT)

Versant Venture Management, LLC reduced to a holding in Veracyte Inc by 33.33%. The sale prices were between $22.1 and $28.56, with an estimated average price of $24.94. The stock is now traded at around $28.27. The impact to a portfolio due to this sale was -9.94%. Versant Venture Management, LLC still held 2,410,815 shares as of .

Reduced: Audentes Therapeutics Inc (BOLD)

Versant Venture Management, LLC reduced to a holding in Audentes Therapeutics Inc by 31.03%. The sale prices were between $35.12 and $41, with an estimated average price of $38.42. The stock is now traded at around $34.30. The impact to a portfolio due to this sale was -3.21%. Versant Venture Management, LLC still held 553,916 shares as of .

Reduced: CymaBay Therapeutics Inc (CBAY)

Versant Venture Management, LLC reduced to a holding in CymaBay Therapeutics Inc by 49.87%. The sale prices were between $6.05 and $13.66, with an estimated average price of $11.36. The stock is now traded at around $6.81. The impact to a portfolio due to this sale was -2.37%. Versant Venture Management, LLC still held 543,753 shares as of .

Here is the complete portfolio of Versant Venture Management, LLC. Also check out:

1. Versant Venture Management, LLC's Undervalued Stocks
2. Versant Venture Management, LLC's Top Growth Companies, and
3. Versant Venture Management, LLC's High Yield stocks
4. Stocks that Versant Venture Management, LLC keeps buying

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.